Revive Therapeutics Ltd. announced the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19. Dr. Joel Moody has over 15 years of experience in clinical research in oncology (breast and ovarian cancer), sickle cell disease, Human T-Lymphotrophic Virus, Types I and II, cholera, and tuberculosis. He brings international expert knowledge and experience in clinical and epidemiological studies. During his career, Joel has helped to launch and manage global phase I - IV clinical studies, including large scale morbid-mortality trials. Joel trained in oncology, tropical and infectious diseases, and internal medicine and completed fellowships at the Lunenfeld-Tanenbaum Research Institute in Mount Sinai Hospital/University of Toronto and the Instituto de Medicina Tropical "Alexander von Humboldt"/Universidad Peruana Cayetano Heredia (Lima, Peru).